Lyell Immunopharma : FDA Clears IND Application for Phase 1 Trial for LYL132 in Solid Tumors

By Michael Dabaie

Lyell Immunopharma Inc. said the U.S. Food and Drug Administration cleared an investigational new drug application to begin a Phase 1 clinical trial for LYL132 in solid tumors.

The company is developing the therapy with GlaxoSmithKline. LYL132 is an investigational T-cell receptor therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1.

Lyell will manufacture LYL132, and GlaxoSmithKline will conduct the Phase 1 trial.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

01-24-22 0849ET